The Consumer of Humans
Name
nuhu-tsanni22-cmsw-sm-2023-thesis.pdf
Description
Thesis PDF
Size
165.95 KB
Format
Adobe PDF
Checksum (MD5)
102989b3af10535be06bb47c34ebab06
Author(s)
Tsann, Abdullahi
Advisor(s)
Greenwood, Veronique
Date Issued
September 2023
Publisher
Massachusetts Institute of Technology
Abstract
For decades, a dearth of scientific research, inadequate treatment and diagnostic tools have slowed progress in the fight to control tuberculosis globally. Scientists have developed important drugs, such as isoniazid, rifampin, and pyrazinamide, against the disease. But these drugs must be taken for several months, are sometimes ineffective, and can cause debilitating side effects. What’s more, if people don’t finish their treatments, it can lead to multidrug-resistant tuberculosis (MDR-TB), a form of the disease that is resistant to two of the four common drugs against TB, or, even more worryingly, extensively drug-resistant tuberculosis (XDR-TB), a form of the disease against which broader anti-TB drugs are powerless. Now, advances in immunology, chemistry, and biomolecular engineering are helping scientists to gain better insight into the complex cellular processes of Mycobacterium tuberculosis and the disease it causes. This could pave the way for the development of innovative diagnostics, vaccines, and new treatments for these tuberculosis superbugs. This thesis examines why tuberculosis kill millions of people till this day and scientists’ best efforts alone can’t win the war.
MIT Department
Massachusetts Institute of Technology. Program in Comparative Media Studies/Writing
Massachusetts Institute of Technology. Graduate Program in Science Writing
Terms of Use
In Copyright - Educational Use Permitted
Copyright retained by author(s)
Persistent DSpace Link
